BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced new data will be presented on Locked Nucleic Acid (LNA) based antisense oligonucleotide programs directed against, the androgen receptor (AR), hedgehog pathway GLI2, and beta-catenin. The Company will also present data related to its Customized PEG linker program. These targets and activities are linked to a broad spectrum of cancers.
